6 Results for "

Capivasertib

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "Capivasertib" in MCE Product Catalog:

89
89 Cited Publications
Cat. No.: HY-15431
CAS No.: 1143532-39-1
Purity:  99.95%
Synonyms: AZD5363
Target:  

Akt Autophagy

Research Areas:  

Cancer

Capivasertib (AZD5363) is an orally active and potent pan-AKT kinase inhibitor with IC50 of 3, 7 and 7 nM for Akt1,Akt2 and Akt3, respectively.
loading...
    loading...
Cat. No.: HY-15431A
CAS No.: 1143532-51-7
Synonyms: (R)-AZD5363
Target:  

Akt

Research Areas:  

Cancer

(R)-Capivasertib ((R)-AZD5363) is the R-enantiomer of Capivasertib (HY-15431) .
loading...
    loading...
Cat. No.: HY-164460
CAS No.: 1204181-93-0
Target:  

Pim

Research Areas:  

Cancer

AZD1897 is a PIM1, PIM2, and PIM3 inhibitor with IC50 values of less than 3 nM for these three PIM kinases. AZD1897 exhibits anticancer activity and synergistically inhibits the activity of acute myeloid leukemia (AML) cells in combination with Capivasertib (HY-15431). This synergistic inhibitory effect is achieved through the inhibition of the mTOR and MCL1 pathways .
loading...
    loading...
Cat. No.: HY-15431R
CAS No.: 1143532-39-1
Synonyms: AZD5363 (Standard)
Research Areas:  

Cancer

Capivasertib (Standard) is the analytical standard of Capivasertib. This product is intended for research and analytical applications. Capivasertib (AZD5363) is an orally active and potent pan-AKT kinase inhibitor with IC50 of 3, 7 and 7 nM for Akt1,Akt2 and Akt3, respectively.
loading...
    loading...
Cat. No.: HY-15431S
Synonyms: AZD5363-d4
Capivasertib-d4 (AZd5363-d4) is the deuterium labeled Capivasertib (HY-15431). Capivasertib (AZD5363) is an orally active and potent pan-AKT kinase inhibitor with IC50 of 3, 7 and 7 nM for Akt1,Akt2 and Akt3, respectively.
loading...
    loading...
Cat. No.: HY-181670
WH23 is a dehydrogenase/reductase SDR family member 11 (DHRS11) inhibitor with IC50 values of 0.037 μM. WH23 binds to DHRS11, forming a hydrogen bond with the enzyme’s His210 residue. WH23 suppresses androgen receptor mRNA and protein expression, reduces c-Myc expression, and inhibits cancer cell proliferation. WH23 inhibits PI3K/AKT signaling by reducing phosphorylation of PDK1, AKT, mTOR, and ERK. WH23 enhances Capivasertib (HY-15431)-induced cytotoxicity and apoptosis. WH23 can be used for the research of luminal androgen receptor-positive triple-negative breast cancer .
loading...
    loading...